Roche’s Rozlytrek Wins NMPA Approval for NTRK Fusion Gene-Positive Tumors
Swiss pharmaceutical giant Roche announced that it has received marketing approval from the National Medical...
Drug
Kira Pharmaceuticals’ KP104 Receives Orphan Drug Designation for PNH Treatment
Sino-US biotech Kira Pharmaceuticals announced that it has received an Orphan Drug Designation (ODD) from...
Takeda’s Alunbrig Prescribed in China for ALK+ NSCLC Treatment
Japan-based Takeda Pharmaceutical Co., Ltd (TYO: 4502) announced that its lung cancer therapy Alunbrig (brigatinib)...
MabPharm’s CMAB015 Biosimilar Receives NMPA Approval for Clinical Study
Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...
Nestle Launches China’s First Cancer-Focused FSMP Product Oral Impact Su Yi Su
Switzerland-based Nestle announced the launch of China’s first “foods for special medical purposes” (FSMP) product...
Nuance Pharma Initiates Phase I Study for Ketorolac IV Infusion (NTM-001)
China-based Nuance Pharma announced the initiation of subject enrollment and the first drug infusion in...
Henlius Biotech’s HanBeiTai Biosimilar of Avastin Accepted for CDE Review
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Center for Drug Evaluation (CDE) has...
Brii Biosciences’ COVID-19 Antibody Cocktail Effective Against Omicron BA.4/5 and BA.2.12.1
China-based Brii Biosciences Ltd (HKG: 2137) announced that its anti-COVID-19 antibody cocktail amubarvimab + romlusevimab...
Sihuan Pharma’s Xuanzhu Bio Files for Fulvestrant-Piroxetine Combo in Advanced Breast Cancer
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...
SinoPharm CNBG’s F61 Monoclonal Antibody Receives NMPA Clinical Trial Approval
SinoPharm CNBG Wuhan Institute of Biological Products Co., Ltd’s F61, a recombinant broad-spectrum novel coronavirus...
Henlius Biotech’s Hanquyou Approved in Australia for HER2-Positive Cancers
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received marketing approval from Australia’s...
Hengrui Medicine’s SHR-1802 + SHR-1316 Combo Receives NMPA Approval for Solid Tumor Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Betta Pharmaceuticals Enrolls First Patient in BPI-442096 Phase I Study for Solid Tumors
China-based Betta Pharmaceuticals (SHE: 300558) announced that the first subject has been enrolled in a...
Hengrui Medicine’s SHR-A1811 Combo Receives NMPA Approval for HER2+ NSCLC Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Sirnaomics’ STP705 Receives Approval for Liver Cancer Trial in Taiwan
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced that it has received approval from...
GenFleet Therapeutics’ GFH018 Receives CTA Approval for Two Clinical Trials in China
Shanghai-based biotech company GenFleet Therapeutics announced that two clinical trial applications (CTAs) for its drug...
NMPA Approves Genuine Biotech’s Azvudine for COVID-19, Fosun Pharma Inks Licensing Deal
China’s National Medical Products Administration (NMPA) has conditionally approved HeNan Genuine Biotech Co., Ltd’s azvudine...
I-Mab Doses First Patient in Global Phase I Study for TJ-CD4B in Solid Tumors
I-Mab (NASDAQ: IMAB), a Nasdaq-listed company since 2020, announced that the first patient has been...
Rona Therapeutics Licenses Sanofi’s siRNA Platform for Global Development
Shanghai-based RNA therapeutics specialist Rona Therapeutics has entered into a licensing agreement with French pharmaceutical...
Luye Pharma’s LY01005 Meets Phase III Trial Goals in Breast Cancer Treatment
China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for LY01005...